About
Roles and Affiliations: Jonathan Chernoff is the Cancer Center Director and Senior Vice President at Fox Chase Cancer Center, part of Temple University Health System. He holds the Stanley P. Reimann Chair in Oncology Research and serves as an adjunct professor at Drexel University School of Medicine and the University of Pennsylvania. His research focuses on cancer signaling pathways, tumor suppression mechanisms, and translational oncology.
Education and Credentials: Chernoff earned a BA in Molecular Biophysics and Biochemistry from Yale University (1978), followed by an MD and PhD in Biochemistry from Mount Sinai School of Medicine (1984). He completed residencies in internal medicine and clinical oncology at the University of Pittsburgh and Johns Hopkins, respectively, followed by a postdoctoral fellowship at Harvard University.
Research Interests: Chernoff’s lab investigates Rac1 signaling in melanoma, p21-activated kinases in cancer, the Hippo tumor suppressor pathway, and Kras isoform-specific signaling. His work bridges basic science and clinical applications, emphasizing translational research, precision medicine, and immunotherapy.
Awards and Recognition: Notable honors include AAAS Fellowship (2017), the Stanley P. Reimann Chair (2008–present), and the Pennsylvania Drug Discovery Award (2013). He has chaired multiple national and international scientific committees.
Advisees and Grants: Chernoff has trained dozens of postdoctoral and graduate students, including Dorothy Benton (Drexel). He leads grants in cancer signaling and epigenetics, with active collaborations across academia and industry.
Labs and Teams: His lab at Fox Chase focuses on cell growth and movement mechanisms, with key personnel including Cristina Uribe-Alvarez and Daniela Araiza-Olivera. Research programs emphasize signaling reprogramming and cancer disparities.
